TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS

The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell di...

Full description

Saved in:
Bibliographic Details
Main Authors ZANCANELLA, Manuel, XU, Qing, YU, Ming, LI, Zhe
Format Patent
LanguageEnglish
Published 26.07.2023
Online AccessGet full text

Cover

Loading…
Abstract The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
AbstractList The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Author LI, Zhe
YU, Ming
XU, Qing
ZANCANELLA, Manuel
Author_xml – fullname: ZANCANELLA, Manuel
– fullname: XU, Qing
– fullname: YU, Ming
– fullname: LI, Zhe
BookMark eNrjYmDJy89L5WSwCQnydI509vF0VnD29w3wD_VzCVZwDFbw8AwO8fdzVfB1DfGI9NENCXL0C3ZzDXIMdlXw9PPwdPIM8Q8K5mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8VGORgZGBgaGpgbGTsbEqAEARtErtg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID ZA202001503B
GroupedDBID EVB
ID FETCH-epo_espacenet_ZA202001503B3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:45:42 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_ZA202001503B3
Notes Application Number: ZA20200001503
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230726&DB=EPODOC&CC=ZA&NR=202001503B
ParticipantIDs epo_espacenet_ZA202001503B
PublicationCentury 2000
PublicationDate 20230726
PublicationDateYYYYMMDD 2023-07-26
PublicationDate_xml – month: 07
  year: 2023
  text: 20230726
  day: 26
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies Global Blood Therapeutics, Inc
RelatedCompanies_xml – name: Global Blood Therapeutics, Inc
Score 3.4795394
Snippet The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the...
SourceID epo
SourceType Open Access Repository
Title TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230726&DB=EPODOC&locale=&CC=ZA&NR=202001503B
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFPVNpzLnBxWkb0VZu9SCQ9o0pZW1HW0n215G00XQh264iv--17A5X_QtJHDcHdxHLne_ANxizj0vekRolqlzzUDfqHGSzzVuCQxwD8IyJG5BGBF_ZDyPe-MGvG9mYSRO6JcER0SLKtDeK-mvl9silit7K1d3_A23Fk9e1nfV9e247mruEtV1-mwYuzFVKe1PbTVK6jOJpqc7O7CLabRZWwN7ceqplOXvkOIdwd4QqZXVMTRE2YIDuvl5rQX74frBG5dr21udwGOWBHRCBwFVaBwO41HkpoqdKn6QZnHElJBl_mSgZYkdpR5L7JQpQeQHTpDFSXoKNx7LqK8hG7MfmWdTe8uxfgbNclGKNiiCFKjP_NUqMLZynVhmj3AUBl3WvWHm-Tl0_qbT-e_wAg5r_dVlyy65hGb18SmuMN5W_Foq6hsqjX3P
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5qFetNq6L1FUFyC0qTbgxYJNkkZDWPkmyl7aUk6Qp6SIuN-PedhNZ60duyC8PswDx35luAG4y5Z3mPCMXQ1UzR0DYqGUlnSmYIdHD3wtBq3IIgJN5Qexr1Rg14X8_C1DihXzU4ImpUjvpe1vZ6sSli2XVv5fI2e8Ot-aPL-7a8yo6rruYukW2r7wwiO6Iypf2JKYdxdVaj6anWFmxjiK1X2uC8WNVUyuK3S3H3YWeA1IryABqiaEOLrn9ea8NusHrwxuVK95aH8MBjRsfUZ1SiUTCIhqGdSGYieSzhUehIgcO9sa_w2AwT14nNxJFY6DGL8ShOjuDadTj1FGRj-nPn6cTccKweQ7OYF-IEJEFylGf6auToWzOVGHqPZJgyoMm60_Q0PYXO33Q6_x1eQcvjgT_1Wfh8BnuVLKsSZpecQ7P8-BQX6HvL7LIW2jc8UoDC
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=TRICYCLIC+COMPOUNDS+AS+HISTONE+METHYL-TRANSFERASE+INHIBITORS&rft.inventor=ZANCANELLA%2C+Manuel&rft.inventor=XU%2C+Qing&rft.inventor=YU%2C+Ming&rft.inventor=LI%2C+Zhe&rft.date=2023-07-26&rft.externalDBID=B&rft.externalDocID=ZA202001503B